-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 13, Shaanxi Panlong Pharmaceutical Group Co.
The announcement stated that the 14th meeting of the third board of directors held by the company reviewed and approved the "Proposal on Canceling the Subsidiary Gansu Panlong Pharmaceutical Co.
According to the announcement, according to the actual operation and business conditions of the wholly-owned subsidiary Gansu Panlong Pharmaceutical Co.
According to the 2020 annual performance report of Panlong Group, during the reporting period, the company achieved operating income of 670,058,900 yuan, an increase of 9.
It is worth noting that as of December 31, 2020, its subsidiary Gansu Panlong had total assets of 169,639.
However, Panlong Pharmaceutical Group stated that the cancellation of Gansu Panlong will not have a significant impact on the company's overall business development and profitability, and will not harm the interests of the company and shareholders.